Study: Narcolepsy Medication Found to Improve Adult ADHD Symptoms
October 21, 2026
An investigational narcolepsy medication called ALKS 7290, an orexin 2 receptor (OX2R) agonist, offers a new therapeutic approach for ADHD, according to results from a recent Phase 1B proof-of-concept study. ALKS 7290 is the first OX2R agonist to demonstrate clinically meaningful improvements in ADHD symptoms in adults with the condition, according to the drugβs manufacturer Alkermes plc.1
βOX2R agonists will represent an entirely new class of ADHD treatment, breaking the traditional barrier between stimulants and non-stimulant treatment,β says Greg Mattingly, M.D., a consultant on the Phase 1 and upcoming Phase 2 trials.
Stimulants remain a first-line treatment for ADHD in adults. However, not all patients tolerate the side effects of or see benefits from stimulant medications. According to an ADDitude survey of more than 11,000 adults with ADHD, 78% of respondents taking amphetamines and 70% of those taking methylphenidate experienced some side effects, compared to 66% of adults taking non-stimulant medications.
How OX2R Agonists Work
The drug works by selectively binding to and activating orexin type 2 receptors, proteins in the brain that regulate alertness, arousal, and appetite. This targeted approach could minimize potential side effects and drug misuse, according to Mattingly.
βUnlike traditional stimulants, orexin 2 receptor agonists have no direct effect on dopamine reuptake or release,β says Mattingly, Associate Clinical Professor in the Department of Psychiatry at the Washington University School of Medicine. βOrexin 2 receptor agonists modulate pathways in the brain that are associated with vigilance, reward, and alertness while decreasing impulsivity. By minimizing direct effects on dopamine reuptake or release, they are considered to have a lower abuse potential.β
The two-week double-blind, parallel-group trial included 50 adults with ADHD and 88 adults without. Participants with ADHD were randomly assigned to receive ALKS 7290 at a total daily dose of 20 mg or 50 mg in split doses or placebo.
As early as day six, patients taking ALKS 7290 demonstrated clinically meaningful improvements in ADHD symptoms, as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), and in overall ADHD severity, as measured on the Clinical Global Impression-Severity Scale (CGI-S).
By day 14, treatment with ALKS 7290 reduced median baseline AISRS total scores by 14 points for the 20 mg dose and 19 points for the 50 mg dose. Median CGI-S scores declined by one point with the 20-mg dose and two points with the 50-mg dose.
ALKS 7290 was generally well tolerated at both doses, with mild side effects including insomnia, dizziness, change in sustained attention, and constipation.
Using an Orexin 2 Receptor Agonist to Treat Coexisting Conditions
The ORX2 agonist also shows promise in treating narcolepsy type 1 (NT1), a common co-occurring condition with ADHD. (Approximately 25% of people with narcolepsy have ADHD.).2 In August, the U.S. Food and Drug Administration approved Orzeyful (oveporexton), a first-in-class OX2R agonist tablet indicated to treat narcolepsy type l (NT1) in adults.3 Takeda Pharmaceuticals, Orzeyfulβs manufacturer, expects the drug to be available in November 2026, pending DEA scheduling.
NT1 is a chronic sleep disorder, characterized by excessive daytime sleepiness (EDS), sudden sleep attacks, cataplexy, and sleep disruptions, resulting from a deficiency in orexin-producing neurons.4
ADHD and narcolepsy share several overlapping symptoms related to arousal and wakefulness. Before becoming standard ADHD treatment, stimulants like amphetamine and methylphenidate were used to treat excessive daytime sleepiness found in narcolepsy patients.5
βOur longest surveillance of the safety of amphetamine comes from following people with narcolepsy for their entire lives,β says ADHD expert William Dodson, M.D., LF-APA. Today, Ritalin (methylphenidate) and Adderall (amphetamine) are both central nervous system stimulant medications approved for the treatment of ADHD and narcolepsy in adults and children.
While it is too soon to know if the OX2R agonist used to treat narcolepsy will likewise evolve into a standard ADHD treatment, the parallels to stimulant medications are clear.
βWhatβs exciting for clinicians was the fact that ALKS 7290 had dose-related improvement in ADHD symptoms with dramatic improvement seen early and sustained throughout the two-week study,β says Mattingly, founding partner of St. Charles Psychiatric Associates. βWhile preliminary, the level of improvement obtained with this molecule after two weeks was similar to what is typically seen after four to six weeks in a trial of methylphenidate or amphetamine molecules for ADHD treatment.β
Results from a Phase 2 clinical trial evaluating the efficacy and safety of ALKS 7290 in adults with ADHD are expected in 2027.
Sources
1 Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). Press Release. September 21, 2026. Accessed October 15, 2026. https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-positive-phase-1b-results-demonstrating
2 Ren, Jiafeng, Zhao, Xianchao, Su, Changjun, et. al. (2024). ADHD in narcolepsy: A closer look at prevalence and ties. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2023.105471
3 FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms. Press Release. August 5, 2026. Accessed October 15, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
4 Krahn, L.E., Zee, P.C., Thorpy, M.J. (2022) Current understanding of narcolepsy 1 and its comorbidities: what clinicians need to know now. Adv Ther. https://doi.org/10.1007/s12325-021-01992-4
5 Konofal, Eric. (2024). From past to future: 50 years of pharmacological interventions to treat narcolepsy. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2024.173804